PCR results for PML/RARα expression in CR bone marrow samples after treatment with liposomal ATRA
| . | No. of patients PCR negative/no. of patients tested (%) . | |
|---|---|---|
| Low-sensitivity PCR (10−3 level) . | High-sensitivity PCR (10−4level) . | |
| At time of CR confirmation4-150 | 9/14 (64%) | 2/9 (22%) |
| Newly diagnosed | 5/6 (83%) | 1/8 (12%) |
| Relapsed | 4/8 (50%) | 1/1 |
| Any time at CR without chemotherapy4-151 | 9/14 (64%) | 8/12 (67%) |
| Newly diagnosed | 5/6 (83%) | 7/11 (64%) |
| Relapsed | 4/8 (50%) | 1/1 |
| . | No. of patients PCR negative/no. of patients tested (%) . | |
|---|---|---|
| Low-sensitivity PCR (10−3 level) . | High-sensitivity PCR (10−4level) . | |
| At time of CR confirmation4-150 | 9/14 (64%) | 2/9 (22%) |
| Newly diagnosed | 5/6 (83%) | 1/8 (12%) |
| Relapsed | 4/8 (50%) | 1/1 |
| Any time at CR without chemotherapy4-151 | 9/14 (64%) | 8/12 (67%) |
| Newly diagnosed | 5/6 (83%) | 7/11 (64%) |
| Relapsed | 4/8 (50%) | 1/1 |
PCR = polymerase chain reaction; PML/RARα = promyelocytic leukemia/retinoic acid receptor-alpha; CR = complete remission; ATRA = all-trans retinoic acid.
PCR was performed on first bone marrow sample that confirmed the CR, on days 21 to 81 (median, day 43) from start of liposomal ATRA.
PCR was assayed anytime during CR before patients received chemotherapy combining the results at CR plus results obtained later during CR. Tests were performed on days 21 to 132 (median, day 53) from start of liposomal ATRA.